Which drugs will work for your patient subgroups?
Effective innovation, R&D productivity, and hitting sales forecasts all depend on knowing which drugs will work in which patient subgroups.
Many of the most expensive late-stage clinical trial failures are due to the inability to show sufficient clinical efficacy. This is often a failure to recruit the right patients who will respond to a drug targeting a specific mechanism.
Even when approved, getting a new drug prescribed and defending a price point in an outcomes-based remuneration model requires biomarker-based tools to identify people who are most likely to benefit from a treatment.
Accurate patient stratification is fundamental – it helps choose the right target product profile and generates mechanistic biomarkers that accelerate and de-risk clinical development and product launch.